Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Autolus Therapeutics plc

AUTL Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2021โ€“FY2025

Last close ยท Oct 23, 2026

$1.54

2.5%
Compare
Revenue Total sales reported in the income statement.
$75.4M
644.9% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’358.9%
2,026.8ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$288M
Free cash flow Cash from operations minus capital spending.
โˆ’$303M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$410M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$1.06 EPS (TTM)

What Autolus Therapeutics plc does

No business description yet.

Legal name
Autolus Therapeutics plc
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 27, 2026
Accession ยท CIK
0001730463-26-000038
0001730463

Revenue and margins

Autolus Therapeutics plc had $75.4M of revenue in fiscal 2025, up 644.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$303M in fiscal 2025, โˆ’401.4% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Autolus Therapeutics plc returned โ€” to shareholders in fiscal 2025. The diluted share count rose 4.3%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Autolus Therapeutics plc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $310M$382M$240M$588M$301M
Interest coverage โˆ’127.6xโˆ’16.1xโˆ’4.0xโˆ’26.0xโˆ’7.4x
Current ratio โ€”9.2x6.2x10.9x5.9x
Quick ratio โ€”9.2x6.2x10.8x5.5x
Total assets โ€”$490M$375M$783M$589M
Total liabilities โ€”$192M$264M$355M$411M
Shareholders' equity $313M$299M$111M$427M$178M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โ€” โœ• โœ“ โœ•
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โ€” โœ• โœ“ โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โœ• โœ•
Revenue rose relative to assets โ€” โ€” โ€” โœ“ โœ“
F-score โ€” / 3โ€” / 4โ€” / 64 / 82 / 8
Accruals ratio โ€”โˆ’7.5%โˆ’14.5%โˆ’2.5%โˆ’0.6%
Altman Z'' โ€”0.29โˆ’6.37โˆ’0.36โˆ’6.27

5 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue โ€” โ€” $1.7M $10.1M $75.4M
Gross profit โ€” โ€” $1.7M โˆ’$1.3M โˆ’$21.0M
Research and development $111M $117M $130M $138M $118M
Operating income โˆ’$141M โˆ’$143M โˆ’$180M โˆ’$241M โˆ’$271M
Interest expense $1.1M $8.9M $45.1M $9.3M $36.7M
Pretax income โˆ’$142M โˆ’$149M โˆ’$208M โˆ’$219M โˆ’$286M
Income tax $0.1M $0.3M โˆ’$0.0M $1.5M $2.0M
Net income โˆ’$142M โˆ’$149M โˆ’$208M โˆ’$221M โˆ’$288M
Net income to common โˆ’$142M โˆ’$149M โˆ’$208M โˆ’$221M โˆ’$288M
Diluted EPS โˆ’$1.97 โˆ’$1.57 โˆ’$1.20 โˆ’$0.86 โˆ’$1.08
Diluted shares 0.07B 0.09B 0.17B 0.26B 0.27B
Cash flow
Cash from operations โˆ’$118M โˆ’$112M โˆ’$146M โˆ’$206M โˆ’$284M
Capital expenditure $8.9M $10.8M $11.0M $22.1M $19.0M
Free cash flow โˆ’$127M โˆ’$123M โˆ’$157M โˆ’$228M โˆ’$303M
Depreciation and amortization $8.5M $7.4M $6.6M $7.6M $8.3M
Stock-based compensation $9.9M $12.0M $11.2M $15.5M $14.4M
Balance sheet
Cash and short-term investments $310M $382M $240M $588M $301M
Current assets โ€” $426M $275M $661M $436M
Current liabilities โ€” $46.4M $44.7M $60.7M $73.4M
Inventory โ€” โ€” $0.0M $4.1M $33.2M
Property and equipment, net โ€” $35.2M $34.9M $49.6M $63.6M
Intangible assets โ€” โ€” $0.0M $12.4M $19.8M
Total assets โ€” $490M $375M $783M $589M
Total liabilities โ€” $192M $264M $355M $411M
Shareholders' equity $313M $299M $111M $427M $178M
Margins
Gross margin โ€” โ€” 100.0% โˆ’12.5% โˆ’27.8%
Operating margin โ€” โ€” โˆ’10,583.1% โˆ’2,385.6% โˆ’358.9%
EBITDA margin โ€” โ€” โˆ’10,196.5% โˆ’2,311.0% โˆ’347.9%
Net margin โ€” โ€” โˆ’12,272.3% โˆ’2,180.5% โˆ’381.4%
FCF margin โ€” โ€” โˆ’9,221.0% โˆ’2,256.4% โˆ’401.4%
Returns
Return on capital employed โ€” โˆ’32.3% โˆ’54.3% โˆ’33.4% โˆ’52.5%
Return on equity โˆ’45.4% โˆ’48.6% โˆ’101.6% โˆ’81.9% โˆ’95.0%
Return on assets โ€” โˆ’30.4% โˆ’48.1% โˆ’38.1% โˆ’41.9%
Return on tangible equity โˆ’45.4% โˆ’49.8% โˆ’186.9% โˆ’53.2% โˆ’181.6%
Growth
Revenue growth โ€” โ€” โ€” 496.0% 644.9%
Share count change โ€” 31.8% 83.1% 46.7% 4.3%
Financial health
Interest coverage โˆ’127.6x โˆ’16.1x โˆ’4.0x โˆ’26.0x โˆ’7.4x
Current ratio โ€” 9.2x 6.2x 10.9x 5.9x
Quick ratio โ€” 9.2x 6.2x 10.8x 5.5x
Capital allocation
Capex / revenue โ€” โ€” 647.0% 218.1% 25.3%
Stock comp / revenue โ€” โ€” 659.8% 152.9% 19.2%
Quality scores
Piotroski F-score โ€” โ€” โ€” 4.0 2.0
Altman Z'' โ€” 0.3 โˆ’6.4 โˆ’0.4 โˆ’6.3
Accruals ratio โ€” โˆ’7.5% โˆ’14.5% โˆ’2.5% โˆ’0.6%

Source: SEC EDGAR XBRL filings (CIK 0001730463). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open